Journal Scans
Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
Intensified Chemotherapy Effective in Early Unfavorable Hodgkin’s Lymphoma
B von Tresckow, A Plutschow, M Fuchs, B Klimm, J Markova, A Lohri, Z Kral, R Greil, MS Topp, J Meissner, JM Zijlstra, M Soekler, H Stein, HT Eich, RP Mueller, V Diehl, P Borchmann, A Engert
20120023
2012 Jan 23
J Clin Oncol
Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial
J Clin Oncol. 2012 Jan 23;[Epub Ahead of Print], B von Tresckow, A Plutschow, M Fuchs, B Klimm, J Markova, A Lohri, Z Kral, R Greil, MS Topp, J Meissner, JM Zijlstra, M Soekler, H Stein, HT Eich, RP Mueller, V Diehl, P Borchmann, A Engert
Abstract
SUMMARY
OncologySTAT Editorial Team
Standard chemotherapy for early unfavorable Hodgkin’s lymphoma (HL)— four cycles of ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine) and 30 Gy involved-field radiotherapy (IFRT)—results in 80% long-term tumor control. In their multicenter HD14 trial, the German Hodgkin Study Group (GHSG) attempted to improve outcomes by using escalated BEACOPP (BEACOPPesc)—bleomycin, etoposide, Adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone.Eligible patients had stage IA, IB, or...
